Atopic dermatitis is one of the most common and frustrating skin conditions in dogs. Understanding how it is diagnosed, what treatment options are available, and why allergy testing matters can make a profound difference in your dog's quality of life.
Canine atopic dermatitis (CAD) is a chronic, genetically predisposed inflammatory skin disease associated with elevated immunoglobulin E (IgE) antibodies to environmental allergens such as pollen, dust mites, mold spores, and dander. It affects an estimated 3–15% of the general dog population and accounts for up to 58% of all dogs seen for dermatologic conditions. Unlike a simple rash or one-time reaction, atopic dermatitis is a lifelong condition that waxes and wanes with allergen exposure and environmental changes.
The underlying mechanism involves a defective skin barrier that allows allergens and microbes to penetrate more easily, triggering an abnormal immune response with excessive cytokine release — particularly interleukin-31 (IL-31), a key driver of the itch sensation. This itch-scratch cycle causes secondary trauma, skin infections, and progressive skin thickening that can dramatically reduce a dog's comfort and quality of life.
While any dog can develop atopic dermatitis, certain breeds are genetically predisposed. These include:
Atopic dermatitis typically appears between 6 months and 3 years of age, though it can develop at any point. There is no sex predisposition. Clinical signs may be seasonal (appearing only during pollen season, for example), nonseasonal, or nonseasonal with seasonal flares. The hallmark sign is pruritus — intense, persistent itching — that often precedes visible skin changes.
The most commonly affected areas are the paws, face, ears, armpits, groin, and the flexural surfaces of the front legs. Over time, repeated scratching and licking leads to secondary lesions including hair loss (alopecia), redness (erythema), scaling, crusting, skin thickening (lichenification), and darkening (hyperpigmentation). Secondary bacterial (Staphylococcus) and yeast (Malassezia) infections are extremely common and can significantly worsen the clinical picture. In some dogs, chronic or recurrent ear infections (otitis) may be the only visible sign.
| Location | Common Signs |
|---|---|
| Paws & feet | Licking, chewing, redness between toes, brown saliva staining |
| Face & muzzle | Rubbing, redness around eyes and lips |
| Ears | Recurrent otitis, head shaking, dark discharge |
| Armpits & groin | Redness, rash, hair loss from scratching |
| Belly & inner thighs | Erythema, papules, lichenification over time |
| Skin overall | Scaling, crusting, hyperpigmentation in chronic cases |
Diagnosing canine atopic dermatitis is a process of exclusion rather than a single definitive test. There is no blood test or skin test that confirms atopy on its own. Instead, veterinarians rely on the patient's signalment, clinical history, physical examination findings, and the systematic ruling out of other causes of pruritus — including flea allergy dermatitis, food allergy, sarcoptic mange, Malassezia dermatitis, and contact dermatitis.
The most widely used diagnostic framework is Favrot's Criteria, a set of eight clinical features validated by prospective studies. When at least five of these criteria are met and other diagnoses have been excluded, a diagnosis of canine atopic dermatitis is highly likely, with a reported sensitivity of 85% and specificity of 79%.
Favrot's Criteria — 5 or more = likely atopic dermatitis
Note: These criteria do not apply to food-induced atopic dermatitis.
A food elimination trial (typically 8–12 weeks on a novel protein or hydrolyzed diet) is often recommended alongside the diagnostic workup, since food-induced atopic dermatitis can look identical to environmental atopy and may coexist with it in the same patient. Only after food allergy has been adequately ruled out can a confident diagnosis of environmental atopic dermatitis be made.
Allergy testing — whether intradermal or serologic — does not diagnose atopic dermatitis. Its purpose is to identify which specific allergens are triggering the immune response in an already-diagnosed atopic dog, so that a customized allergen-specific immunotherapy (ASIT) vaccine can be formulated. Testing results are only meaningful when the identified allergens are consistent with the dog's clinical history and seasonal pattern.
Intradermal allergy testing is considered the gold standard by most veterinary dermatologists. Small amounts of individual allergen extracts are injected just under the skin of the shaved lateral thorax. A positive reaction — a raised wheal — indicates that mast cells in the skin have IgE antibodies bound to them for that allergen. IDAT requires sedation, must be performed by a board-certified veterinary dermatologist, and requires that certain medications (antihistamines, corticosteroids, Apoquel) be discontinued weeks in advance. Despite these requirements, it provides highly accurate, geographically relevant results because the allergen panel can be customized to local environmental allergens.
Serum allergy testing (also called blood allergy testing or RAST/ELISA testing) measures allergen-specific IgE levels in the blood. It does not require sedation, can be performed by any veterinarian, and is not affected by ongoing medications in the same way as IDAT. While it is more convenient and accessible, it is generally considered slightly less accurate than intradermal testing, with a higher rate of false positives. However, for many patients — particularly those who cannot safely be sedated or who cannot discontinue medications — serum testing is a practical and effective alternative.
| Feature | Intradermal (IDAT) | Serum (SAT) |
|---|---|---|
| Accuracy | Gold standard | Good; slightly more false positives |
| Sedation required | Yes | No |
| Who performs it | Veterinary dermatologist | Any veterinarian |
| Medication restrictions | Must stop antihistamines, steroids, Apoquel | Minimal restrictions |
| Allergen panel | Customized to local environment | Standardized panels |
| Best for | Definitive allergen ID before immunotherapy | Patients unable to undergo IDAT |
The primary benefit of allergy testing is that it enables the formulation of a personalized allergen-specific immunotherapy (ASIT) vaccine — the only treatment that can actually modify the immune system's response to allergens rather than simply suppressing symptoms. Knowing which allergens are responsible also allows owners to take targeted avoidance measures: using HEPA air purifiers if dust mites are a trigger, avoiding certain parks during peak grass pollen season, or switching to hypoallergenic bedding materials.
Without allergy testing, immunotherapy cannot be formulated, and management is limited to lifelong symptom suppression with medications. While these medications are effective, they do not address the root cause. Allergy testing opens the door to a treatment pathway that may, over time, reduce or eliminate the need for ongoing drug therapy.
Atopic dermatitis cannot be cured, but it can be managed effectively in most cases. Treatment is multimodal — meaning a combination of approaches is almost always more effective than any single therapy. The goals are to control pruritus, reduce inflammation, prevent secondary infections, restore the skin barrier, and, where possible, desensitize the immune system to the underlying allergens.
ASIT is the only treatment that changes the immune system's response to allergens rather than suppressing symptoms. Based on allergy test results, a custom vaccine is formulated containing gradually increasing doses of the offending allergens. It can be administered as injections (every 1–4 weeks) or as oral drops (once or twice daily). Owners should expect 6–12 months before full benefit is seen. The success rate is approximately 60–70%. Side effects are uncommon but can include temporary increased itching, lethargy, or, rarely, anaphylaxis.
Lokivetmab is a caninized monoclonal antibody that neutralizes IL-31, the primary cytokine responsible for the itch sensation in atopic dogs. Administered as a subcutaneous injection every 4–8 weeks, it provides rapid relief (within 24 hours) with a duration of effect lasting 4–8 weeks. It has an excellent safety profile with no known drug interactions, making it suitable for dogs of all ages and health statuses. It is effective for both acute flare management and chronic maintenance.
Oclacitinib is a Janus kinase (JAK) inhibitor that blocks the signaling pathways involved in allergic and pruritic responses. Given orally twice daily for the first two weeks then once daily for maintenance, it provides rapid itch relief (within 4 hours) and is effective for both acute and chronic management. It is approved for dogs 12 months and older. Long-term use requires periodic monitoring for potential effects on immune function. A chewable tablet formulation is now available, reducing client burden.
Modified cyclosporine is an immunosuppressant that reduces T-cell-mediated inflammation. It is given orally once daily and typically takes 4–6 weeks to reach full effect, making it less suitable for acute flares. It is effective for long-term management and can often be tapered to every-other-day dosing once controlled. Side effects include gastrointestinal upset (nausea, vomiting, diarrhea) and, with long-term use, potential immunosuppression. A generic oral solution is now available.
Oral and topical corticosteroids (prednisone, prednisolone, dexamethasone) remain effective and affordable options for short-term control of acute flares. They provide rapid, broad anti-inflammatory relief. However, long-term systemic use carries significant risks including increased thirst and urination, weight gain, muscle wasting, susceptibility to infections, and adrenal suppression. They are best reserved for short-term flare management or as a bridge while waiting for slower-acting therapies to take effect.
Regular bathing (weekly to biweekly) with gentle, hypoallergenic or antimicrobial shampoos reduces allergen load on the skin, removes surface microbes, and soothes inflammation. Topical corticosteroids and calcineurin inhibitors (tacrolimus) can be applied to localized lesions. Omega-3 fatty acid supplements (fish oil) support skin barrier function and have mild anti-inflammatory effects. Topical ceramide-based moisturizers help restore the defective skin barrier that underlies atopic dermatitis.
| Therapy | Onset | Best For | Modifies Disease? |
|---|---|---|---|
| ASIT (Immunotherapy) | 6–12 months | Long-term remission | Yes — only option |
| Cytopoint (Lokivetmab) | Within 24 hrs | Acute & chronic itch control | No |
| Apoquel (Oclacitinib) | Within 4 hrs | Acute & chronic itch control | No |
| Cyclosporine | 4–6 weeks | Chronic management | No |
| Corticosteroids | Hours | Short-term flare control | No |
| Topicals & bathing | Days | Adjunct / skin barrier support | Partially |
Even well-controlled atopic dogs experience flares. Recognized triggers include increased pollen counts, flea exposure, dietary changes, new environmental allergens, and secondary skin or ear infections. When a flare occurs in a dog that is otherwise well managed, the first step is to investigate the cause before escalating medications. Addressing the underlying trigger — treating a concurrent bacterial pyoderma, implementing strict flea control, or identifying a new food ingredient — often resolves the flare without the need for additional antipruritic therapy.
Secondary bacterial and yeast infections are among the most common reasons for flares and treatment failures. Staphylococcal pyoderma and Malassezia dermatitis both cause significant pruritus in their own right and can make an otherwise controlled atopic dog appear unresponsive to therapy. Cytology (a simple in-clinic test using tape strips or swabs) can quickly identify these infections, which are then treated with appropriate antibiotics or antifungals — topically when possible to minimize systemic drug exposure and antimicrobial resistance.
A diagnosis of atopic dermatitis is not a sentence to a life of constant suffering. With the right combination of therapies, the vast majority of atopic dogs can live comfortable, happy lives. The key is a committed, proactive approach: regular veterinary check-ins (at least every 6 months), consistent use of prescribed therapies, prompt treatment of secondary infections, and open communication with your veterinarian when signs change.
Allergen-specific immunotherapy, while requiring patience, offers the best chance of long-term improvement and potential reduction in medication dependence. For dogs whose owners pursue allergy testing and commit to immunotherapy, many achieve excellent control — and some achieve near-complete remission over time.
At Vets ASAP Mobile Veterinary Care, we can evaluate your dog's skin in the comfort of your own home — where the allergens they live with every day are right there with us. If your dog is showing signs of chronic itching, recurrent ear infections, or persistent skin problems, don't wait. Early diagnosis and a thoughtful management plan make a real difference.
We come to you. Schedule a skin evaluation with Dr. Caren today — no waiting rooms, no car rides, just expert care at home.